Date:1/31/2011

operating income$81,654$79,184Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Non-GAAP operating income $86,358$79,634Non-GAAP income before taxesGAAP income before taxes$81,510$77,382Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Non-GAAP income before taxes$86,214$77,832Non-GAAP net incomeGAAP net income$58,992$54,409Restructuring, deal integration and closing costs6,598450Contingent consideration income(1,894)-Tax benefit associated with non-GAAP items(1,939)(110)Non-GAAP net income$61,757$54,749Non-GAAP net income per common share assuming dilutionGAAP net income per common share assuming dilution$2.32$2.08Non-GAAP items after tax per common share assuming dilution$0.11$0.02Non-GAAP net income per common share assuming dilution$2.42$2.10Presented below are additional Constant Currency performance measures.  We measure different components of our business at constant currency.  We believe this information is useful for investors because it allows for an evaluation of the Company without the effect of changes in foreign exchange rates.  These results convert our local foreign currency operating results to the US Dollar at constant exchange rates of $1.20 per Euro, and 110 Yen to the $1.00.  They also exclude the results of our foreign currency hedging program described in Note 7 to our consolidated financial statements in our Form 10-K.  Non-GAAP revenuesGAAP revenue$506,661$476,326Foreign currency effects(29,788)(30,481)Non-GAAP revenue - constant currency$476,873$445,845Non-GAAP net incomeNon-GAAP net income, adjusted for restructuring and deal integration costs and contingent consideration income$61,757$54,749Foreign currency effects(12,589)(15,711)Income tax associated with foreign currency effects3,5764,798Non-GAAP net income - constant currency52,74443,836Non-GAAP net income per common share assuming dilutionNon-GAAP net income per commo
'/>"/>

SOURCE Haemonetics Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
2. Neogen Reports 33% Increase in Net Income
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
7. GeneLink Reports Third Quarter Results
8. Imagenetix, Inc. Reports Second Quarter 2011 Results
9. Transgenomic Reports Third Quarter Financial Results
10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010